Pharma

Your Article Summary

See Latest Articles

CEL-SCI Files Patent Application to Support Company's Treatment for More Virulent Strain of H1N1 Swine and Other Influenza Viruses
CEL-SCI, 06/26/09

CEL-SCI CORPORATION announced that it has filed a provisional U.S. patent application covering its L.E.A.P.S. immune therapy drugs for the prevention/treatment of H1N1, swine, bird flu, Influenza A and/or evolving mutants or variants of these viruses. Some experts believe that by the next flu season the swine flu virus will have evolved and/or combined with other viruses to create a much more lethal new virus. That is what happened in the case of the Spanish flu pandemic.

Today in Regulatory Issues...keeping you current

Receive free subspecialty "5-minute updates" via email

Tricare contracts may be re-bid after losing plans protest
American Medical News , 11/25/09

GSK Regulatory Update: Avodart
GlaxoSmithKline, 11/24/09

Baytubes carbon nanotubes in marine coatings help reduce frictional resistance
BayNews International, 11/24/09

 See all of Regulatory Issues